Latest News about REGN
Recent news which mentions REGN
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
December 18, 2023
Tickers
REGN
From Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
December 18, 2023
Tickers
REGN
From Benzinga
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
December 17, 2023
From Motley Fool
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
From InvestorPlace
3 Stocks to Buy Before 2024 That Can Set You Up For Life
December 14, 2023
From Motley Fool
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
From InvestorPlace
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
December 11, 2023
Tickers
REGN
From Benzinga
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
December 08, 2023
Tickers
REGN
From Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
From Motley Fool
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
December 02, 2023
From InvestorPlace
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
December 01, 2023
Tickers
REGN
From Benzinga
11 Analysts Have This to Say About Regeneron Pharmaceuticals
November 28, 2023
Tickers
REGN
From Benzinga
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
From Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
November 16, 2023
From Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
November 16, 2023
Tickers
REGN
From Benzinga
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
From InvestorPlace
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
From InvestorPlace
2 Soaring Stocks to Buy and Hold
November 09, 2023
From Motley Fool
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
November 06, 2023
From Benzinga
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review
November 03, 2023
Tickers
REGN
From Benzinga
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
From Benzinga
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple
November 02, 2023
From Benzinga
From Motley Fool
Earnings Scheduled For November 2, 2023
November 02, 2023
From Benzinga
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
October 31, 2023
Tickers
REGN
From Benzinga
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
October 30, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.